Skip to content

Prophylactic Intravenous Tranexamic Acid on Perioperative Blood Loss in Pregnant Women Undergoing Cesarean Section

Effect of Preoperative Prophylactic Intravenous Tranexamic Acid on Perioperative Blood Loss in Pregnant Women Undergoing Cesarean Section : A Randomized Controlled Trial

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07078942
Enrollment
98
Registered
2025-07-22
Start date
2025-07-20
Completion date
2026-12-31
Last updated
2025-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnant Women Undergoing Cesarean Delivery

Keywords

tranexamic acid, blood loss, pregnant women, cesarean delivery

Brief summary

The purpose of this study is to asses the effect of preoperative prophylactic intravenous tranexamic acid on perioperative blood loss in pregnant women undergoing cesarean section

Interventions

DRUGTranexamic Acid

Tranexamic Acid 1 g intravenous preoperation

OTHERPlacebo

normal saline 20 ml intravenous preoperation

Sponsors

Chulalongkorn University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* pregnant women with gestational age 37-42 weeks * undergoing cesarean delivery with indication as follows: placenta previa, severe preeclampsia, myoma uteri, fetal macrosomia, polyhydramnios, grand multiparity ≥ 5 deliveries, prolonged labor, etc.

Exclusion criteria

* history of allergy to tranexamic acid * history of venous thromboembolism (Deep vein thrombosis, Pulmonary embolism) * history of arterial thrombosis (Myocardial infarction, Stroke) * history of seizure, convulsion * have underlying of cardiovascular, renal or liver disease * using of antiplatelet or anticoagulant within 1 week before operation * placenta accreta spectrum * abruptio placenta * Eclampsia or HELLP (Hemolysis Elevated Liver Low Platelet) syndrome * Failed operative vaginal delivery * Multifetal gestation

Design outcomes

Primary

MeasureTime frameDescription
Blood lossFrom enrollment to the end of operationblood loss in ml

Secondary

MeasureTime frameDescription
early postpartum hemorrhageFrom starting operation to 24-hour postoperationpercentage of early postpartum hemorrhage
delayed postpartum hemorrhageFrom starting operation to 6 weeks postpartumpercentage of delayed postpartum hemorrhage
Adverse effectsfrom enrollment to 6 weeks postpartumpercentage of adverse effects
Neonatal outcomesfrom starting operation to 10 minutes after birthApgar scores (0 is the minimum value and 10 is maximum value, and higher scores mean a better outcome)

Countries

Thailand

Contacts

Primary ContactVorapong Phupong, M.D.
vorapong.p@chula.ac.th+6626492115
Backup ContactThawit Suesakulpaisal, M.D.
tsm.2539@gmail.com026492115

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026